The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all.

It's been a sad week for Vertex, Inc. ( NASDAQ:VERX ), who've watched their investment drop 14% to US$20.08 in the ...

One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

Fintel reports that on November 4, 2025, Citizens maintained coverage of Vertex (NasdaqGM:VERX) with a Market Outperform ...

Discover Vertex’s Q3 2025 earnings: strong cloud growth, new CEO, $150M share buyback, and AI investments amid guidance cuts.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know.

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...

Analysts expect Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.35. Investors in Vertex Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of ...

This strengthens Google’s position against rivals such as Microsoft and AWS as enterprises seek faster, more reliable ways to ...